Safety and pharmacodynamic efficacy of eculizumab in aneurysmal subarachnoid hemorrhage (CLASH): A phase 2a randomized clinical trial.

21 , 22 In a randomized clinical trial, treatment of SAH patients with interleukin-1 receptor antagonists resulted in decreased peripheral inflammation, but the reduction in inflammatory CSF parameters did not reach statistical significance, possibly because of a small sample size. 23 , 24 These results are in line with our findings, in which complement activity is highly reduced in serum, but a similar effect is not found in CSF.

also in 111,027 other papers